IJ Pharmaceutical Research
Scopus by Title (Ref)
1. A newly developed high-performance thin layer chromatographic method for determination of remdesivir, favipiravir and dexamethasone, in spiked human plasma: comparison with the published methods
- Abdelfatah R.M. , et al.
2. Tautomerism, ionization, ESIPT and aggregation: what determines emission of hydroxypyrazinecarboxamides?
- Gerasimova T.P. , et al.
3. Neuroprotective propensity of N-(5-chloro-2-hydroxyphenyl)-2-(morpholin-4-yl-methyl) benzamide, an inventive calcineurin inhibitor, in biological models of Parkinson’s disease
- Nivya R.M. , et al.
4. In-vivo implementation of the HPTLC methodology to rat plasma for the concurrent determination of a novel combination therapy for the management of COVID-19 (favipiravir and nitazoxanide)
- Edrees F.H. , et al.
5. ZnO-carbon nanomaterials-based hybrid platforms for electrochemical sensing of favipiravir as an antiviral medication for COVID-19
- Neshati M. , et al.
6. Dispersive Solid Phase Extraction Using Folic Acid Coupled with a Modified Glassy Carbon Electrode for Electrochemical Sensing of Favipiravir in Urine and Water Samples
- Avan A.A. , et al.
7. A Novel Stability-Indicating HPLC Method with Kinetics Study for the Concurrent Analysis of Anti‐Hypertensive Drug Combination of Atenolol and Indapamide
- Rabadiya V.A. , et al.
8. Harnessing new and stable green carbon nanoprobes enables a selective and reliable approach to fluorimetric analysis of favipiravir drug in human plasma
- Alzahrani E. , et al.
10. A DOE- based sustainable UPLC method for the Quantification of COVID-19 antiviral, Favipiravir, co-administered with prednisolone in rat Plasma, including pharmacokinetic study greenness and whiteness Assessment
- Salem AlSalem H. , et al.
11. DETERMINATION OF ANTIVIRAL-DRUG FAVIPIRAVIR FROM BIOLOGICAL SAMPLES BY USING MOLECULAR IMPRINTED POLYMER-BASED ELECTROCHEMICAL SENSOR
- Kanbeş-Di̇Ndar Ç. , et al.
13. Switch from The Traditional RPLC Method to the Green RPLC Methods in The Determination of The Ionization Constant (pKa) of Favipiravir
- Daldal Y.D. , et al.
14. Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned
- Sürmelioğlu N. , et al.
15. Response surface experimental design for simultaneous chromatographic determination of two antiviral agents “Favipiravir and Remdesivir” in pharmaceuticals and spiked plasma samples
- Abdel Hakiem A.F. , et al.
16. Acid-base reaction-based dispersive solid phase extraction of favipiravir using biotin from biological samples prior to capillary electrophoresis analysis
- Safari E. , et al.
17. Insights into the sustainability of liquid chromatographic methods for favipiravir bioanalysis: a comparative study
- Mostafa A. , et al.
18. QbD-Based Stability-Indicating RP-HPLC Method Development and Validation for the Estimation of Favipiravir—An Eco-Friendly Approach
- Siri Chandana M. , et al.
20. Validation of the Spectrophotometric Method for the Determination of Favipiravir for the Quality Control of Tablets
- Scrypynets Y.V. , et al.
21. Favipiravir, remdesivir, and lopinavir: metabolites, degradation products and their analytical methods
- Hoseininezhad-Namin M.S. , et al.
22. Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation
- Batubara A.S. , et al.
23. Synchronous spectrofluorimetric determination of favipiravir and aspirin at the nano-gram scale in spiked human plasma; greenness evaluation
- Batubara A.S. , et al.